Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Iodine I-131 with or without Selumetinib in Treating Patients with Recurrent or Metastatic Thyroid Cancer

This randomized phase II trial studies how well iodine I-131 works with or without selumetinib in treating patients with thyroid cancer that has returned or has spread from where it started to other places in the body. Many thyroid cancers absorb iodine. Due to this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as part of standard practice. It is thought that the more thyroid tumors are able to absorb radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors to shrink. Selumetinib may help radioactive iodine work better in patients whose tumors still absorb radioactive iodine. It is not yet known whether iodine I-131 is more effective with or without selumetinib in treating thyroid cancer.
Not Available
II
Gilbert, Jill
NCT02393690
VICCHN1817

WAPPS- Hemo (Web Accessible Population Pharmacokinetics Service - Hemophilia)
Protocol ? Phase 2: Testing and Validation

Not Available
II
Wheeler, Allison
NCT02061072
VICCNCBH1824

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer

The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
Not Available
II
Ciombor, Kristen
NCT03384940
VICCGI1825

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed / Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant
Not Available
III
Reddy, Nishitha
NCT03138499
VICCPCL1829

Alpha-1-Proteinase Inhibitor Human in Preventing Development of Steroid-Refractory Graft Versus Host Disease in Stem Cell Transplant Participants

This phase II trial studies the side effects and how well alpha-1-proteinase inhibitor human works in preventing development of graft versus host disease in stem cell transplant participants. Graft versus host disease is the most common serious complication after receiving a bone marrow transplant. Alpha-1-proteinase inhibitor human may help prevent the inflammatory immune response from graft versus host disease and damage to the skin, liver, stomach, and / or intestines.
Not Available
II
Jagasia, Madan
NCT03459040
VICCBMT1833

Optimization of Cancer Therapy Using Immune Effector Cells

Hematologic

Hematologic
N/A
Oluwole, Olalekan
VICCBMT1834

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Kidney (Renal Cell)

This study is a randomized Phase 2 evaluation of CB-839 in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic Renal Cell Carcinoma.
Kidney (Renal Cell)
II
Davis, Nancy
NCT03428217
VICCURO1835

Islet Cell and ST2 Axis Dysregulation in Post-Transplant Diabetes Mellitus

Not Available
N/A
Engelhardt, Brian
NCT03415139
VICCBMT1836

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed / Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Multiple Cancer Types

This study will be conducted as an assessment of the safety and preliminary activity of eribulin mesylate in pediatric participants with relapsed / refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), or Ewing sarcoma (EWS) to determine whether each cohort warrants further investigation.
Pediatrics, Sarcoma
II
Borinstein, Scott
NCT03441360
VICCPED1838

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents with Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission

Multiple Cancer Types

This randomized clinical trial studies how well web-based physical activity intervention works in improving long term health in children and adolescents with newly diagnosed acute lymphoblastic leukemia that shows a decrease in or disappearance of signs and symptoms. Regular physical activity after receiving treatment for cancer may help to maintain a healthy weight and improve energy levels and overall health.
Pediatric Leukemia, Pediatrics
N/A
Esbenshade, Adam
NCT03223753
COGALTE1631

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: